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Commonpreclinicalmodels for testing anticancer treatment include culturedhuman tumor cell lines inmonolayer, and
xenografts derived from these cell lines in immunodeficient mice. Our goal was to determine how similar the
xenografts are compared with their original cell line and to determine whether it is possible to predict the stability of a
xenograft model beforehand. We studied a selection of 89 protein markers of interest in 14 human cell cultures and
respective subcutaneous xenografts using the reverse-phase protein array technology. We specifically focused on
proteins and posttranslational modifications involved in DNA repair, PI3K pathway, apoptosis, tyrosine kinase
signaling, stress, cell cycle, MAPK/ERK signaling, SAPK/JNK signaling, NFκB signaling, and adhesion/cytoskeleton.
Using hierarchical clustering, most cell culture-xenograft pairs cluster together, suggesting a global conservation of
protein signature. Particularly, Akt, NFkB, EGFR, and Vimentin showed very stable protein expression and
phosphorylation levels highlighting that 4 of 10 pathways were highly correlated whatever the model. Other proteins
were heterogeneously conserved depending on the cell line. Finally, cell line models with low Akt pathway activation
and low levels of Vimentin gave rise to more reliable xenograft models. These results may be useful for the
extrapolation of cell culture experiments to in vivo models in novel targeted drug discovery.
Translational Oncology (2016) 9, 313–321© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/bync-nd/4.0/).
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Developing a new drug from original idea to the launch of a finished
product is a complex process which can take 12 to 15 years and costs
more than $1 billion [1]. During lead discovery, an intensive search
ensues to find a drug-like small molecule or biological therapeutic,
typically termed a development candidate, that will progress into
preclinical and, if successful, into clinical development and ultimately
be a marketed medicine. Common preclinical models include
cultured human tumor cell lines in monolayer, and xenografts
derived from the same human lines in immunodeficient mice [2,3].
Monolayer cell cultures used in cancer biology and drug discovery are
cost-effective and necessary for high-throughput screening but are
generally highly reductionist (for its inability to capture the
complexity and heterogeneity of a cancer) [4]. In vivo modeling
provides essential tumor-host interactions and is a more accurate
means of modeling human cancer in terms of toxicity and in vivo
antitumor effectiveness. Its importance as models for drug testing and
translational study has been recognized by many biomedical and
pharmaceutical companies [5], and their validation and optimization
are therefore essential. However, in vivo modeling has several
drawbacks such as necessity of adapted structures and highly qualified
personal or limitations on engraftment rates that might limit
their applicability.
The features of models used in cancer research constitute critical
tools for elucidating mechanisms of cancer development, as well as for
assessment of putative cancer therapies. Although cell cultures studies
allow a high-throughput screening, their major drawbacks, which
make in vivo assessment necessary, are the lack of tumor
microenvironment and the lack of heterogeneity observed in primary
cancer [6]. Cell line xenograft models present only a murine stroma,
and if subclones can coexist, primary cancer heterogeneity is probably
lost. Nevertheless, animal models are necessary for preclinical
research, and therefore, their validation and optimization are essential.
High-throughput screening approaches are largely used to
characterize cell lines and tumors and identify biomarkers that
could be associated to diagnosis or prognosis [7]. The most currently
used analyzed the RNA content (transcriptome) or DNA modifica-
tion (genome) through dedicated microarrays or, more recently,
high-throughput sequencing. However, in mammalian species, most
of the regulatory modifications occur at the level of proteins, and it is
widely accepted that their amount and their posttranslational
modifications regulate cell signaling pathways that govern cell
behavior and their capacity to proliferate and escape from treatment
[8,9]. Other posttranslational modifications and notably histone
methylation and acetylation could also affect gene expression and
therefore protein expression [10]. Moreover, whereas we do not
expect major change in the genome of cells once they are grafted on
mice, the (phospho-)proteome can evolve via the interaction with the
microenvironment, the limit in oxygen and nutriments, and the
signals exchange with the stroma [11–13]. These differences could
account for discrepancies sometime reported between cell response to
treatment and results in vivo [1,3]. However, despite the increasing
interest for proteome, the methods to characterize it are still limited.
Notably, the analysis of the phosphoproteome by mass spectrometry
is promising but still very challenging [14] and requires large amounts
of protein lysate (several mg) that are difficult to obtain from in vivo
studies or patient samples [15]. In this study, we therefore used
reverse-phase protein array (RPPA), a technology using
high-throughput antibody-based detection. It requires only a fewmicrograms of protein lysate and allows assessing protein expression
and their main modification status in a highly quantitative manner
[9,16]. In contrast to mass spectrometry, this technology can analyze
hundreds of samples simultaneously on the same array and thus
generate large datasets to identify potential diagnostic, prognostic,
and therapeutic markers in human cancer [17]. We applied this
technology to a panel of 14 cell lines and their corresponding
xenografts to assess how similar the xenografts are compared with
their original cell line and to determine whether it is possible to
predict the stability of a xenograft model beforehand. We explored a
selection of proteins and modifications involved in 10 different
signaling pathways: DNA repair, PI3K pathway, apoptosis, tyrosine
kinase signaling, stress signaling, cell cycle, MAPK/ERK signaling,
SAPK/JNK signaling, NFκB signaling, and adhesion/cytoskeleton.
Material and Methods
Cell Culture
Fourteen human cell lines were used: nine high-grade glioma cell
lines (SF763, SF767, U251MG, U87MG, SNB19, MO59K, T98G,
U118MG, and CB193), two colorectal cancer cell lines (HCT116
and HT29), two melanoma cell lines (SK28 and LU1205), and one
head and neck cancer cell line (Hep-2). SF763, SF767, U251MG,
and U87MG glioma cell lines were given by Dr. C. Delmas (Centre
Claudius Regaud, Toulouse, France). U87MG cell line was used to
obtain a U87MG-luciferase cell line (U87MG-L). SNB19 glioma cell
line was given by N. Auger (Institut Curie, Paris, France). T98G,
U118MG, and CB193 cell lines were kindly provided by G.
Pennarun (CEA, Grenoble, France). MO59K and MO59J cell lines
were given by N. Foray (Centre Léon Bérard, Lyon, France).
HCT116, HT29, SK28, LU1205, and Hep-2 cell lines were
obtained from ATCC (Manassas, VA). All culture reagents were
purchased from GIBCO (Invitrogen, Cergy-Pontoise, France). Cells
were grown in Dulbecco’s modified Eagle’s medium (with 4500 mg/l
glucose and L-glutamine) supplemented with sodium pyruvate 1%,
nonessential amino acids 1%, gentamicin 10 μg/ml, and 10% fetal
calf serum in a humidified incubator containing 5% CO2 at 37°C.
Xenograft Models
Xenografts derived from cell lines were obtained by injecting 4 ×
106 cells of each cell line described above into the flank of adult
female nude mice (Janvier, Le Genest Saint Isle, France). The animals
were housed in our animal facility. There were six animals per cage
under controlled conditions of light and dark cycles (12 hours:
12 hours), relative humidity (55%), and temperature (21°C). Food
and tap water were available ad libitum. When subcutaneous tumors
reached approximately 500 mm3, mice were sacrificed. An
anatomopathologist has evaluated the percentage of tumoral cells as
being more than 80% for all cell line–based xenografts studied
(using blind microscopy analysis of several samples per tumor).
The Local Committee on Ethics of Animal Experimentation
approved all experiments.
Antibodies and Validation
The 65 antibodies used are listed in Table S.1. We explored 39 total
proteins and 26 phosphoproteins and then calculated 24 ratios of
phosphoproteins on total proteins. These proteins and modifications
were chosen as representative of 10 different signaling pathways: DNA
repair, PI3K pathway, apoptosis, tyrosine kinase signaling, stress
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signaling, and adhesion/cytoskeleton (Table S.1). To ensure that our
antibodies were of sufficient quality, we confirmed their specificity by
Western blotting on a large panel of cell lines treated with ligands and
inhibitors. Antibodies with only a single or dominant band on Western
blotting were validated and used in RPPA.
Preparation of Cell Lysates
Cell lines were scraped from plates in hot Laemmli buffer (50 mM
Tris pH = 6.8, 2% SDS, 5% glycerol, 2 mM DTT, 2.5 mM EDTA,
2.5 mM EGTA, 2× Perbio Halt Phosphatase inhibitor cocktail,
Roche Protease inhibitors complete MINI EDTA-free, 4 mM sodium
orthovanadate, 20 mM sodium fluoride). Tumors were mechanically
disrupted in the same lysis buffer (1 ml for 80 mg of sample) using a
CK28 Precellys (Bertin Technologies, Montigny le Bretonneux,
France) at 4°C, 6000 rpm, 60 seconds three times. Extracts were
boiled for 10 minutes at +100°C and spinned for 15 minutes at
13,000 rpm at 15°C. The protein fraction was transferred to a new
tube and spinned again at 13,000 rpm for 5 minutes at 15°C. The
pellet was discarded, and lysates were snap-frozen. Protein concen-
tration was measured using the Reducing Agent Compatible BCA kit
(Pierce, Rockford, IL).
Reverse-Phase Protein Array
Proteins from 14 cell lines were analyzed with 5 replicates for cell
cultures and 6 replicates for subcutaneous xenograft models (2
different locations in 3 different tumors per model). Samples were
printed onto nitrocellulose-covered slides (Schott Nexterion NC-C,
Jena, Germany) with a dedicated arrayer (2470 Arrayer, Aushon
Biosystems, Billerica, MA). Five serial dilutions, ranging from 2 to
0.125 mg/ml, and 4 technical replicates per dilution were used for
each sample. Detection was carried out with specific antibodies or
without primary antibody (negative control) using an Autostainer
Plus (Dako, Trappes, France). Briefly, slides were incubated with
avidin, biotin, and peroxidase blocking reagents (Dako) and then
saturated with TBS supplemented with 0.1% Tween 20 and 5% BSA
(TBST-BSA). The slides were then probed by overnight incubation at
4 °C with primary antibodies diluted in TBST-BSA. The arrays were
washed in TBST and then probed with horseradish peroxidase–coupled
secondary antibodies (Jackson ImmunoResearch, Newmarket, UK)
diluted in TBST-BSA for 1 hour at room temperature. The signal
was amplified by incubating the slides with amplification reagent
(Bio-Rad) for 15 minutes at room temperature. The arrays were then
washed with TBST, probed with Cy5-streptavidin (Jackson
ImmunoResearch) diluted in TBST-BSA for 1 hour at room
temperature, and washed again in TBST. Total protein staining was
achieved by incubating the arrays for 15 minutes in 7% acetic acid
and 10%methanol, rinsing twice in water, incubating for 10 minutes
in Sypro Ruby (Invitrogen), and rinsing again. The processed slides
were dried by centrifugation and scanned with a GenePix 4000B
microarray scanner (Molecular Devices, Sunnyvale, CA). Spot
intensity was determined with MicroVigene 4.0.0.0 software
(VigeneTech Inc., Carlisle, MA). Quantification of the data was
achieved with SuperCurve [18], and the data were normalized against
negative control slides and Sypro Ruby slides.
Statistical Analysis
Statistical analysis was performed using R v2.15.1 (http://
www.cran.r-project.org). The tests were two-sided, with a type Ierror set at α = 0.05. The study of relation between quantitative
parameters was explored by Pearson or Spearman correlation
coefficients according to statistical distribution. To identify makers
differentially expressed (i) between in vitro and in vivo conditions and
(ii) between the two groups of models, Mann-Whitney test was
performed according to sample size and if assumptions of parametric
test are not met. To highlight the most robust changes, studied
markers were considered to be differentially accumulated when (i)
Mann-Whitney test was significant (P b .05) and (ii) the change was
more than 1.5-fold (fold change N1.5). An arbitrary 1.5-fold change
cutoff value means a minimum of 50% of variation in the 2 groups
compared. To explore changes between the three sets of data obtained
for U87MG model, Kruskal-Wallis test was performed followed by
Dunn test for pairwise comparisons (adjustment according to the
Dunn-Sidak correction). Hierarchical clustering of the data was
performed on expression markers for each replicate or mean to
build dendograms (Ward method). Heat maps were drawn using
Gplots library.
Results
Global Similarity between Each Cell Line and Its Respective
Xenograft
We performed a targeted proteomics approach using RPPA to
study how similar the xenograft models are to their respective cell
cultures. A total of 160 samples were analyzed: 14 cell lines (5
replicate extracts per cell line) and corresponding subcutaneous
xenografts (2 fragments per tumor from 3 tumors). Each sample was
printed in five serial dilutions and four technical replicates per
dilution. Arrays were labeled with a selection of 89 highly specific
antibodies: 39 against total proteins, 26 against phosphoproteins, and
24 ratios of phosphoproteins on total proteins were analyzed. The
selected proteins and modifications are involved in 10 different
signaling pathways: DNA repair, PI3K pathway, apoptosis, tyrosine
kinase signaling, stress signaling, cell cycle, MAPK/ERK signaling,
SAPK/JNK signaling, NFκB signaling, and adhesion/cytoskeleton
(Table S1).
Firstly, we checked for the similarity between biological replicates,
that is, between the five replicates for each cell line and between the
six different fragments for each xenograft (two fragments per tumor
from three different mice). For this, the Pearson correlation for each
possible comparison was calculated for in vitro and in vivo samples.
The mean correlations between in vitro replicates ranged from 0.82 to
0.97 and from 0.81 to 0.95 for in vivo replicates. The calculated
standard error of the mean correlations is low (range 0.01-0.03),
strengthening the high similarity among independent biological
replicates. We also calculated the coefficient of variation (CV) for
each sample to evaluate the variability between the biological
replicates. This median CV ranged from 7% to 22% with a median
of 12.6%. This again points to a very good similarity between the
biological replicates. As expected, the CV was higher for in vivo
replicates than for in vitro replicates.
Then, to evaluate the similarity of data obtained in vitro (cell
culture) and in vivo (subcutaneous xenograft), we evaluated the
correlation of RPPA signal in each paired model independently. As
shown in Table 1, each cell culture-xenograft paired data were
statistically correlated, with Pearson correlation coefficients higher
than 0.7 for 12 of the 14 pairs. The SNB19 model is the most
divergent between in vitro and in vivo conditions (correlation
Table 1. Comparison of In Vitro and In Vivo Data for Each Model
Cell Line Cell Origin Correlation between
In Vitro and In Vivo†
Number of Proteins Differentially
Expressed§ and with a Fold Change N1.5
SNB19 Glioblastoma .27 ‡ 27
CB193 Glioma grade III .51 ‡ 18
MO59K Glioblastoma .70 ‡ 16
U118MG Glioblastoma .72 ‡ 11
LU1205 Melanoma .73 ‡ 14
SF763 Glioblastoma .74 ‡ 13
U87MG Glioblastoma .77 ‡ 37
SF767 Glioblastoma .80 ‡ 11
Hep2 Head and neck carcinoma .81 ‡ 11
T98G Glioblastoma .84 ‡ 15
SK28 Melanoma .86 ‡ 6
HT29 Colon carcinoma .87 ‡ 0
U87MG/IC* Glioblastoma .89 ‡ 1
HCT116 Colon carcinoma .90 ‡ 1
U251MG Glioblastoma .93 ‡ 5
* Intracranial orthotopic xenograft.
† Pearson correlation.
‡ P value.
§ Mann-Whitney test (P b .05).
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one (correlation coefficient 0.93). Altogether, these results highlight
the fact that, at least for proteins explored in our study, there is a
global similarity of protein expression and phosphorylation between
cell culture and the corresponding subcutaneous xenograft model.
Four Pathways Highly Conserved Whatever the Cell Line Origin
To assess more in detail the stability of each protein expression and
modification level between cell culture and its respective xenograft
model (14 paired models), we evaluated the correlation of RPPA
signals obtained for each studied marker independently. We found
that 29 markers are highly conserved between in vitro and in vivo
conditions (Pearson test P b .05) with a correlation ranging from 0.54
to 0.92 (Table 2). The P values were then adjusted for multiple
testing using the Sidak correction, which decreased the number of
conserved markers to 11. Akt, EGFR, NFkB, IKK β, and Vimentin
showed very stable protein expression and phosphorylation levels
between cell culture and subcutaneous xenograft models whatever the
model. These proteins clearly highlight 4 of 10 explored signaling
pathways: PI3K pathway, tyrosine kinase signaling, NFκB signaling,
and adhesion/cytoskeleton. After Sidak correction, none of the
proteins involved in DNA repair and stress signaling were found to be
statistically conserved when comparing the 14 xenografts and their
respective cell culture of origin. However, their conservation was
heterogeneous among each cell culture-xenograft pair.
Eight of the 14 Cell Culture-Xenograft Pairs Cluster Together
To further visualize how similar or dissimilar xenografts were
compared with their original cell line, we performed unsupervised
hierarchical clustering analysis of RPPA data (Figures 1 and S.1). By
looking at whether xenografts and cell culture pairs cluster together or
not in the dendrogram, we identified three main groups named as
dissimilar group (SNB19, MO59K, LU1205, CB193, U118MG,
U87MG), near-similar group (HT29, HCT116, SF763, Hep2), and
highly similar group (SK28, SF767, T98G, U251MG). For the
models in the highly similar group, xenografts and cell lines cluster
together, whereas for the models in the dissimilar group, they cluster
far from each other. The models in the near-similar group show close,but not perfect, clustering. As expected, five of the six cell
culture-xenograft pairs of dissimilar group were also the ones showing
lower levels of correlation between cell culture and xenograft
(correlation coefficients b 0.73).
We then determined the proteins that were differentially expressed
between each cell line-xenograft pairs among the 65 tested markers
(Table 1). We only considered significant proteins showing at least a
1.5-fold change in expression to focus on the biologically most
relevant changes [19]. In the pairs from the highly similar and the
near-similar groups, a mean of 9 and 6 markers, respectively, was
statistically differentially expressed between the xenograft and the cell
line, whereas a mean of 21 markers was identified in the pairs from
the dissimilar group. In all three groups, the identified markers were
extremely inconsistent and seem to be specific of each cell
culture-xenograft pair.
We thus conclude that proteins whose expression is highly
conserved between cell lines and xenografts are mostly related to Akt,
NFkB, EGFR, and Vimentin, whereas the proteins that significantly
change upon engraftment are more diverse.
Prediction of Cell Culture-Xenograft Pair Clustering by In Vitro
Proteic Signature Analysis
Next, we wished to assess whether it is possible to identify those cell
cultures that, upon engraftment, represent a relevant model, that is, a
xenograft that closely resembles the cell line of origin in terms of
protein expression. For this, we performed an unsupervised
hierarchical clustering analysis of in vitro data only (Figure 2).
Interestingly, we observed two main clusters of cell cultures.
The first corresponds to the dissimilar group, and the second
combines the near-similar and highly similar groups. We studied the
proteins that are differentially expressed between these three groups
among cell cultures (Figure S.2). We observed few differences
between the near-similar and the highly similar groups, whereas the
dissimilar group is more distinct. Because the near-similar and highly
similar groups here appeared as one single cluster in the in vitro data
and showed few proteic differences, we hereafter called this the similar
group. This suggests that a different pattern of protein exists between
the cell cultures that will give rise to a similar xenografts compared
with those that will give rise to a less conserved xenograft. We then
explored which proteins were differentially expressed between these
two groups of cell lines to identify potential predictive biomarkers. A
Mann-Whitney test revealed that 11 of 65 proteins or phosphopro-
teins (Figures 3 and 4) are significantly differentially expressed
between the two in vitro identified groups (P b .05). We observed
two major relevant variations (fold change N1.5) for PTEN and
Vimentin expression. PTEN expression was increased in the similar
group (increased fold change of 1.8). In agreement with this increase
of PTEN signaling, we observed a downward trend of Akt-Thr308
and Akt-S473 phosphorylations (decreased fold change of 1.2 and
1.3, respectively). Vimentin expression was severely reduced in the
similar group (decreased fold change of 2.4) compared with the dis-
similar group. Furthermore, we could indicate that phosho-H2AX and
Rad21 seemed to be higher in the similar group (increased fold change
of 1.4 for both). Expression of HSP90β, FEN1, integrin β4, MGMT,
and EGFR was also slightly increased in the similar group. In
conclusion, when a cell culture has low Akt and vimentin signaling
levels and relatively high DNA damage response, its engraftment
is more likely to produce a xenograft that is similar to the original
cell culture.
Table 2. Conserved Proteins between In Vitro and In Vivo Whatever the Cell Line Origin
Name Type Description Pearson Correlation P Values P Values after Sidak Adjustment
Phospho-Vimentin (Ser 459) on Vimentin Phosphoprotein/protein Cytoskeleton 0.92 b .001 b .001
Vimentin Protein Cytoskeleton 0.91 b .001 b .001
Phospho-Akt (Thr308) on Akt Phosphoprotein PI3K pathway 0.89 b .001 b .01
Phospho-Akt (Ser473) on Akt Phosphoprotein PI3K pathway 0.89 b .001 b .01
IKK β Protein NF-kB signaling 0.86 b .001 b .01
EGFR Protein Tyrosine kinase signaling 0.86 b .001 b .01
Phospho-EGFR (Thr669) Phosphoprotein Tyrosine kinase signaling 0.84 b .001 b .05
NF-kB p65 Protein NF-kB signaling 0.83 b .001 b .05
Phospho-EGFR (Thr669) on EGFR Phoshoprotein/protein Tyrosine kinase signaling 0.82 b .001 b .05
Akt Protein PI3K pathway 0.81 b .001 b .05
Phospho-NF-kB p65 (Ser536) on NF-kB p65 Phoshoprotein/protein NF-kB signaling 0.81 b .001 b .05
Src Protein Tyrosine kinase signaling, SRC family 0.79 b .001 NS
Phospho-Akt (Ser473) Phosphoprotein PI3K pathway 0.76 b .01 NS
Phospho-EGFR (Tyr 1173) on EGFR Phoshoprotein/protein Tyrosine kinase signaling 0.68 b .01 NS
Phospho-HSP27 (Ser82) Phosphoprotein Stress signaling, MAPK/ERK signaling 0.68 b .01 NS
Hsp90 β Protein Stress signaling 0.66 b .05 NS
PARP Protein DNA repair, apoptosis 0.64 b .05 NS
JunB Protein SAPK/JNK pathway 0.64 b .05 NS
FoxO3a/FKHRL1 Protein Stress signaling, PI3K pathway, cell cycle 0.63 b .05 NS
Phospho-Akt (Thr308) Phosphoprotein PI3K pathway 0.62 b .05 NS
Cleaved PARP on PARP Phoshoprotein/protein DNA repair, apoptosis 0.62 b .05 NS
Phospho-Chk1 (Ser280) on Chk1 Phoshoprotein/protein DNA repair, cell cycle 0.61 b .05 NS
Integrin β4 Protein Cytoskeleton, adhesion 0.6 b .05 NS
Phospho-JunB on JunB Phoshoprotein/protein SAPK/JNK pathway 0.59 b .05 NS
VCP Protein DNA repair, cell cycle, apoptosis 0.59 b .05 NS
FAK Protein Tyrosine kinase signaling, adhesion 0.58 b .05 NS
Phospho-FAK (Tyr861) on FAK Phoshoprotein/protein Tyrosine kinase signaling, adhesion 0.57 b .05 NS
Phospho-histone H2AX (Ser139) on H2AX Phoshoprotein/protein DNA repair, chromatin 0.56 b .05 NS
Phospho-FAK (Tyr925) on FAK Phoshoprotein/protein Tyrosine kinase signaling, adhesion 0.54 b .05 NS
NS, not significant.
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to Subcutaneous Xenograft
U87MG is one of the most frequently used models for testing
therapies for malignant gliomas [20]. This cell line was therefore
assessed through a third model orthotopically engrafted. RPPA signal
of U87MG cell culture model was compared with U87MG
subcutaneous xenograft model but also with U87MG intracranial
xenograft model. The proteins explored in this study were globally
conserved between the three U87MG models (correlation coefficient
0.77-0.89, Table 1). However, hierarchical clustering reveals that theFigure 1. Hierarchical clustering of all data (cell line and xenograft
phosphoproteins, and 24 ratios of phosphoproteins on total protei
representative of DNA repair, PI3K pathway, apoptosis, tyrosine kinas
JNK signaling, NFκB signaling, and adhesion/cytoskeleton. Data obtai
and 6 replicates for subcutaneous xenograft models. For U87MG,
dendrogram was built using Ward method.cell culture model seems to be closer to intracranial model than to
subcutaneous model (Figure 1).
To decipher the differences in protein expression and phosphor-
ylation between these three conditions, a Kruskall and Wallis test
followed by a Dunn test adjusted by Sidak method was done using all
replicates. In agreement with data presented in Table 1 and taking
into account only fold changes N1.5, subcutaneous xenograft
differentially expressed 37 and 32 markers compared with cell culture
and intracranial xenograft respectively, whereas only 1 marker was
differentially expressed between cell culture and intracranial xenograft).We explored a total of 89 proteic markers: 39 total proteins, 26
ns (Table S1). These proteins and modifications were chosen as
e signaling, stress signaling, cell cycle, MAPK/ERK signaling, SAPK/
ned for 14 cell lines were analyzed with 5 replicates for cell cultures
an additional orthotopic model (six replicates) was studied. The
Figure 2. Hierarchical clustering of in vitro data.The mean values
obtained for each explored protein or phosphoprotein for the 14
cell lines were used to build the dendrogram (Ward method). The
first cluster corresponds to the dissimilar group. The second
combines the near-similar and highly similar groups, called here the
similar group.
318 Global Conservation of Protein Status Biau et al. Translational Oncology Vol. 9, No. 4, 2016model, underlining again the high similarity between these two
models for the proteins assessed in this study.
Discussion
Human cancer-derived cell cultures and xenograft tumors are widely
used models in cancer biology and innovative therapeutic studies [3].
There is a growing effort to reduce animal studies and findFigure 3. Differentially expressed proteins between similar and dissi
test was performed (P b .05) to identify makers differentially expre
markers and fold change between similar and dissimilar groups are ireplacement methods to analyze and predict the effects of new
treatments [21]. One alternative model proposed is the use of cell line
cultures. Although it cannot replace all the information generated by
animal models such as the pharmacokinetics and pharmacodynamics
parameter or the impact of angiogenesis and inflammatory response
on tumor growth, cell line studies might provide important
information on intrinsic sensitivity of tumor cells to specific
treatments. However, changes induced by the growth environment
on the main constituents of the signaling pathways and constitutive
stress response could alter the capacity of tumor cells to respond to
treatment. Therefore, identifying markers to select cell lines and
tumor models that do not differ should facilitate the study of the
treatment effects and their mechanisms. Several elements could affect
the transfer and extrapolation of in vitro results to in vivo experiments.
Among them, the stability of tumor cells and xenograft phenotypes
could be a major pitfall. Our objective in this study was to determine
if expression and activation of proteins were involved in DNA repair,
PI3K pathway, apoptosis, tyrosine kinase signaling, stress signaling,
cell cycle, MAPK/ERK signaling, SAPK/JNK signaling, NFκB
signaling, and adhesion/cytoskeleton.
We chose the RPPA technology to study these proteins of interest
because it requires only a few micrograms of protein lysate to study
activation of cell signaling pathways, and allows comparing hundreds
of samples in the same experiment. We could thus include replicate
samples for the cell lines and different tumor regions from multiple
mice for the xenografts to obtain robust data and assess heterogeneity
within and among tumors.milar groups.Among the proteic markers explored, Mann-Whitney
ssed between the two groups of models. Boxplots for identified
ndicated.
Figure 4. Heat map of differentially expressed proteins between similar and dissimilar groups.Expression range from low (white) to high
(black) for the 11 differentially expressed markers between the similar (green) and dissimilar groups (blue).
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replicates both in vitro and in vivo In vitro reproducibility was quite
expected. The high homogeneity in vivo between different areas of
the tumor or different tumors indicates that, in these xenograft
models, the tumors are relatively homogeneous, a characteristic that
facilitates the interpretation of the data but might not reflect the
status of all patient tumors [3].
We also found a global similarity between cell cultures and their
paired xenograft regarding protein expression. Twelve out of 14 pairs
had a correlation coefficient superior to 0.7. Furthermore, a detailed
analysis revealed that Akt, EGFR, NFkB, IKK β, and Vimentin
showed very stable protein expression and phosphorylation levels
between cell culture and subcutaneous xenograft models whatever the
model. These proteins clearly highlight 4 of 10 explored signaling
pathways: PI3K pathway, tyrosine kinase signaling, NFκB signaling,
and adhesion/cytoskeleton.
Gathering evidence has revealed that Akt [22–25] and NF-κB
[26,27] signaling pathways play an important role in cancer
progression, aggressiveness, and resistance to treatment and therefore
represent potential target to improve current treatments. EGF
signaling alterations, and especially its receptor mutation that
increases intracellular signaling, are a major issue in cancer research
over the last decade [28–33]. Vimentin, the major intermediate
filament of mesenchymal cells, is often used as a marker of
mesenchymal ly der ived cel l s or ce l l s undergoing an
epithelial-to-mesenchymal transition (EMT) during both normal
development and metastatic progression [34]. The high conservation
of these four pathways during engraftment suggests that these
pathways are of importance for the tumor and that they might not be
directly influenced by their environment. All other proteins,
including DNA repair proteins, were heterogeneously conserved
depending on the cell line. This finding suggests that for specificstudies on specific proteins with targeted therapies, extrapolation
results from monolayer cultures to xenografts should be cautiously
assessed. These differences could account for discrepancies sometime
reported between cell response to treatment and results in vivo [1,3].
One of the major differences between the cell cultures in monolayer
and tumors is the presence of infiltrating cells (stroma). Not only are
these cells purified with the tumor cells in the tumor and could alter
the protein pattern, but according to their nature, they can differently
affect the tumor cells. The similarity of the cell cultures with the
tumors in the majority of the models indicates that these infiltrating
cells represent only a minor fraction of the tissue and did not affect the
tumor cells. Indeed, histological analyses of the tumors (data not
shown) have described all studied xenografts as homogeneous masses
of cancer cells with minimal stromal infiltration. The percentage of
tumor cells has been evaluated to be more than 80% for all xenografts
with no differences found between groups.
We also identified, after unsupervised hierarchical clustering
analysis of RPPA signal, two clusters of cell lines, for which data
from cell culture and subcutaneous xenograft are either similar or not.
We further studied the factors that differentiate these two groups of
cell lines. We found that cell lines harboring a high level of vimentin
and a low level of PTEN concurrently with a high Akt pathway
activation gave rise to xenografts that were less similar to the original
cell line, probably because they were more sensitive to the
environment change. These proteins are associated with EMT [35].
EMT is a critical event in the induction of cell motility and increased
cell survival under physiological situations like wound healing or
development as well as during invasion and metastasis. Vimentin is an
intermediate filament protein which is characteristically upregulated
in cells undergoing EMT. For decades, vimentin has been considered
as a marker for EMT, and recent studies support the notion that
vimentin is a prerequisite for EMT induction. Our results thus
320 Global Conservation of Protein Status Biau et al. Translational Oncology Vol. 9, No. 4, 2016suggest that cell lines having EMT features produce less reliable
xenografts. Validation of these findings would require a larger series
of cell lines and xenograft models and should include more markers
of EMT.
In the near-similar and highly similar groups, five out of eight
models are PTEN wild type, whereas all models in the dissimilar
group are mutated for PTEN [36–40]. When we look individually at
each model, there is no clear correlation between mutation status and
protein level. All wild-type samples express high levels of PTEN, but
mutant samples can express either high or low levels of PTEN. This
probably depends on the type of mutation (deletion, truncating, or
missense) and the localization of the mutation relative to the antibody
epitope (which is C-terminal). When taken together, the models with
mutant PTEN express globally lower levels of protein compared with
wild type (P = .02). The difference that we observed between the
near-similar/highly similar and the dissimilar groups in terms of
PTEN levels thus probably reflects the mutation status. It would be
interesting to address in a larger panel of models whether PTEN
mutation status by itself can predict the stability of xenograft models.
Another unexpected result that this study highlighted was the effect of
the tumor location on the protein markers. U87MG model is a widely
used glioblastomamodel that was established from a female glioblastoma
patient [20]. Here, we have studied the similarity in protein expression
between three different conditions:monolayer cell culture, subcutaneous
xenograft, and orthotopic (brain) xenograft. Orthotopic xenograft
models, although technically more challenging, are often preferred as
an advanced step in drug development or biological studies [2].
Interestingly, we have shown that, in terms of protein expression,
orthotopic U87MG xenograft was by far more similar to monolayer cell
culture (correlation of 0.89 and cluster together) than the subcutaneous
model. It would be interesting to confirm this in other cancer models
grafted both subcutaneously and orthotopically.
Conclusion
Here we reported a global high conservation of protein expression and
activation between cell culture and xenograft models. In particular,
four pathways were found to be highly correlated among all cancer
models: Akt, NFkB, EGFR, and Vimentin. Other proteins were
heterogeneously conserved depending on the cell line. Cell line
models with low activation of the Akt pathway and low expression
of Vimentin seem to give rise to more stable xenografts. These
results may be useful for the extrapolation of cell culture experiments
to in vivo models notably in novel targeted drug discovery and
biomarkers research.
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